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Abstract 23 
Studies in genetic model organisms have revealed much about the 24 
development and pathology of complex tissues. Most have focused on cell-25 
intrinsic gene functions and mechanisms. Much less is known about how 26 
transformed, or otherwise functionally disrupted, cells interact with 27 
healthy ones towards a favorable or pathological outcome. This is largely 28 
due to technical limitations. We developed new genetic tools in Drosophila 29 
melanogaster that permit efficient multiplexed gain- and loss-of-function 30 
genetic perturbations with separable spatial and temporal control. 31 
Importantly, our novel tool-set is independent of the commonly used 32 
GAL4/UAS system, freeing the latter for additional, non-autonomous, 33 
genetic manipulations; and is built into a single strain, allowing one-34 
generation interrogation of non-autonomous effects. Altogether, our design 35 
opens up efficient genome-wide screens on any deleterious phenotype, 36 
once plasmid or genome engineering is used to place the desired miRNA(s) 37 
or ORF(s) into our genotype. Specifically, we developed tools to study 38 
extrinsic effects on neural tumor growth but the strategy presented has 39 
endless applications within and beyond neurobiology, and in other model 40 
organisms. 41 
 42 
43 
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Introduction 44 
Despite numerous and versatile genetic mosaic strategies available for 45 
genetically amenable model organism Drosophila melanogaster, none up to now 46 
was suited for efficient large-scale screening for cell non-autonomous effects on 47 
a developmentally deleterious genotype. Given the requirement for 48 
combinations of genetic manipulations, non-autonomous effects are more 49 
challenging to investigate yet well known to play crucial roles in development 50 
and disease contexts such as cancer. The challenge applies to any tissue but is 51 
particularly evident in the central nervous system (CNS) due to diversity of cell 52 
types and uniqueness of each lineage with respect to gene expression, size, 53 
projection patterns, as well as lethality frequently associated with their 54 
disruption. A much needed, transformative, new tool would be: (i) a viable 55 
parental stock in which (ii) chosen individual lineages could be (iii) triggered to 56 
assume a deleterious genotype (iv) with temporal control (v) from which point 57 
they would become permanently labeled by a reporter and (vi) with which a 58 
single cross to existing stocks would produce progeny with genetically perturbed 59 
cell types of interest other than the labeled lineages. To illustrate in our specific 60 
case: no available genetic tool allowed large-scale screening for non-autonomous 61 
effects on neural tumor growth as animals harbouring neural tumors cannot be 62 
kept as a stable stock.  63 
Drosophila has been a canvas for pioneering mosaic tools, at the heart of which 64 
lie heterologous binary systems for transcriptional activation or recombination 65 
(Griffin et al. 2014). Transcriptional activation systems include the yeast 66 
transcription factor GAL4 and its binding site, named Upstream Activating 67 
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Sequence (UAS); the bacterial LexA/LexA Operator (LexAop); and the fungal 68 
QF/QUAS system (Brand and Perrimon 1993; Yagi et al. 2010; Potter et al. 2010). 69 
Recombination systems include the bacteriophage Cre recombinase and its loxP 70 
target; the yeast Flippase/Flippase Recognition Target sites (FLP/FRT) and its 71 
variant mFLP5/mFRT71; and other yeast recombinases (KD, R, B2, and B3) and 72 
their cognate recognition sites (Golic and Linquist, 1989; Siegal and Hartl 1996; 73 
Hadjieconomou et al. 2011; Nern et al., 2011). The modularity of binary systems 74 
grants them combinatorial flexibility, and ingenious Boolean logic gates between 75 
recombination and transcriptional activation/silencing systems have expanded 76 
their applications (eg., Struhl and Basler 1993; Lee and Luo 1999; Griffin et al. 77 
2009; Yu et al. 2009; Yagi et al. 2010; Hadjieconomou et al. 2011; Hampel et al. 78 
2011; von Philipsborn et al. 2011; Awasaki et al., 2014). Binary systems have 79 
been extensively employed to perform large-scale screens using publically 80 
available UAS libraries to provide molecular understanding into numerous 81 
conserved cell intrinsic processes (St Johnston 2002; Kawakami et al. 2016). 82 
Genome-wide screens remain to be applied to extrinsic processes modifying an 83 
adverse genotype. 84 
We wished to determine the effects of microenvironment or systemic cues on 85 
tumor progression. To this end we needed to generate reproducible neural 86 
tumors in order to quantitatively assess growth. Tumor reproducibility requires 87 
control over lineage, induction time and consistency of levels of downregulation 88 
of tumor-suppressors and/or upregulation of oncogenes. We therefore aimed at 89 
generating tumors in restricted lineage subsets with a fast inducing event in 90 
parental (F0) animals, independently of GAL4/UAS so that we might employ this 91 
binary system (for which most modules exist in Drosophila, including for near 92 
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genome-wide gain- and loss-of-function, readily available to the community) to 93 
cause non-autonomous perturbations on F1 progeny. Due to possible fate 94 
transformations and expression-level variations of regulatory sequences, we 95 
wanted tumors to become irreversibly labeled under the control of a ubiquitous 96 
and strong regulatory sequence from the time of induction. Various but not all of 97 
these features can be achieved with suppressible/inducible LexA, Q and FLP 98 
systems (Weigmann and Cohen 1999; Yagi et al. 2010; Riabinina et al. 2015). 99 
Maintenance of an F0 stock with capacity for tumor induction requires 100 
suppression of the deleterious genotype until desired. However, whilst the 101 
lexAGAD derivative (superscript indicating the GAL4 activation domain) can be 102 
suppressed by GAL80, it is not compatible with continuous non-autonomous 103 
gene inductions via GAL4 as these would also be affected. Also, alleviation of QF 104 
suppression by quinic acid, or estrogen induction of FLPEBD (superscript 105 
indicating an estrogen-binding domain) requires ingestion and metabolization of 106 
the effector molecule, resulting in relatively long induction kinetics and 107 
variability, thus impairing reproducibility in the fast-developing fly tumor 108 
models (Weigmann and Cohen 1999; Potter et al. 2010).  109 
Our design presented achieves the desired features via the employment of two 110 
very efficient transcriptional termination sequences (STOP cassettes) upstream 111 
of an oncogenic sequence and reporter. Each STOP cassette is flanked by 112 
recombinase target sequences selective for two distinct recombinases, one 113 
constitutively expressed in selected lineages, conferring spatial specificity; the 114 
other whose expression is induced by heat-shock (hs), conferring rapid temporal 115 
resolution. We tested and refined the new genetic tools by recapitulating two 116 
well-established Drosophila neural tumor models, one generated by 117 
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downregulation of the homeodomain transcription factor Prospero (Pros), which 118 
can lead to tumorigenesis in all neural lineages (of which there are around 100 119 
per central brain lobe); another by downregulation of the NHL-domain protein 120 
Brain tumor (Brat), whose depletion leads to tumorigenesis specifically in so-121 
called type II lineages (of which there are eight per brain lobe (Figure 1−figure 122 
supplement 1) (Sousa-Nunes et al. 2010). Starting from the units presented here 123 
our design can be multiplexed beyond two to produce further spatial 124 
intersections, or multiple temporal steps, along with any assemblies of gene 125 
expression downstream (downregulation and/or upregulation, plus reporter 126 
labeling). This strategy is therefore of broad interest, applicable to other tissues, 127 
organisms and biological questions, opening-up large-scale screening for non-128 
autonomous effects. 129 
 130 
Results 131 
FOFO tool design features 132 
Key to the design of this tumor-generating tool is that expression of deleterious 133 
sequences by the ubiquitous strong actin5C promoter, was blocked by not one 134 
(as commonly done), but two stringent STOP cassettes. Each STOP cassette was 135 
flanked by the selective recombination sites FRT and mFRT71, specifically 136 
recognized by FLP and mFLP5, respectively (Hadjieconomou et al. 2011). We 137 
called this design “FOFO”, for Flp-Out-mFlp5-Out. The prediction was that 138 
expression would be unblocked only in the presence of the two Flippases, with 139 
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spatiotemporal control achieved by lineage-restricted expression of FLP and hs-140 
induction of mFLP5 (Figure 1a).  141 
We wanted our tumor-generating tool to induce expression not only of 142 
oncogenes but to also allow downregulation of tumor suppressors, in addition to 143 
a reporter gene (in this case enhanced green fluorescent protein, EGFP). 144 
Multicistronic expression of oncogenic and reporter proteins can be easily 145 
achieved by sandwiching T2A peptide (Gonzalez et al. 2011; Diao and White 146 
2012) codons between coding sequences (cds). We therefore focused on 147 
achieving a layout that reconciled strong reporter expression with gene 148 
downregulation by short hairpin artificial microRNAs (miRs). Artificial miRs 149 
consist of 21 bp sequences designed for RNA interference, embedded into a 150 
sequence backbone of a naturally occurring miR; they are very effective in 151 
downregulating gene expression (more so than long double-stranded RNAs; Ni et 152 
al. 2011), can be transcribed by RNA polymerase II (Pol II) (Lee et al. 2014), and 153 
can be concatenated for synergistic effect (Chen et al. 2007). We placed the EGFP 154 
cds downstream of an intron as this increases transcript expression (Haley et al. 155 
2010) and has the additional advantage of being able to host miRs without 156 
disrupting transcript stability by their processing, unlike when miRs are placed 157 
in the 3’ untranslated region (3’UTR) (Bejarano et al. 2012).  158 
Wishing to study strictly cell non-autonomous effects employing the GAL4/UAS 159 
system, we included miRs targeting GAL4 as well as those targeting a tumor 160 
suppressor (two miRs per target). Therefore, if the GAL4 expression domain 161 
overlapped with the tumor domain, GAL4 would be silenced within the tumor. 162 
miRs targeting the neural tumor suppressors pros or brat were used for tumor 163 
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induction and those targeting CD2 were used as control (Yu et al. 2009). To 164 
minimize position effects and enhance expression, all constructs generated for 165 
this study were flanked by gypsy insulators and integrated into the Drosophila 166 
genome by PhiC3-mediated transgenesis, selecting sites reported to produce low 167 
basal and high induced expression (Markstein et al. 2008). 168 
The utility of this design lies in its combination with two distinct Flippases plus a 169 
desired GAL4 transgene in a single organism (Figure 1b, F0 left). Once 170 
assembled, this stock can then be crossed to any other carrying a UAS-transgene 171 
(Figure 1b, F0 right). The spatially-restricted FLP will excise the first STOP 172 
cassette with a domain reproducibility that depends on enhancer reliability and 173 
strength as well as efficacy of the excision activity. In any case, neither reporter 174 
nor deleterious sequences should be expressed due to the additional STOP 175 
cassette. Consequently, until heat-shock, F0 and its F1 progeny should contain a 176 
single mFLP5-Out cassette within the FLP-expressing domain. F1 should also 177 
express the UAS-transgene in the GAL4 domain, and not express the miRs or 178 
reporter (Figure 1b, F1 left). Following F1 heat-shock (Figure 1b, F1 middle), the 179 
mFRT71-flanked STOP cassette should be excised (without spatial constraints, 180 
its efficacy depending on heat-shock duration); following which the miRs and 181 
reporter can be expressed but only within the FLP-expressing domain (Figure 182 
1b, F1 right). If the GAL4 domain overlaps with the FLP spatial domain (as 183 
schematized in Figure 1b), strictly non-autonomous effects can still be studied 184 
since GAL4 expression will be wiped-out therein by the GAL4miRs (Figure 1b, F1 185 
right). A more naturalistic schematic illustrating brain tumours and GAL4 driven 186 
in all glia is depicted in Figure 1c. 187 
 188 
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Efficacy of STOP cassettes 189 
Central to the success of this strategy is the efficacy of the STOP cassettes. For 190 
each we used tandem transcriptional terminators, as others before us.  Whereas 191 
some degree of STOP leakiness can be afforded to simply label cells or to 192 
generate a deleterious genetic perturbation by means of a cross, it is absolutely 193 
incompatible with our aim of harbouring a “locked” deleterious perturbation 194 
within a stable stock. We tested a few transcriptional terminators until we 195 
obtained the tightly controlled expression necessary. 196 
Removal of the lamin cds from the STOP cassette used in Flybow 197 
(Hadjieconomou et al. 2011) resulted in failure to terminate transcription 198 
despite concatenated hsp70Aa and hsp27 terminators, seen by EGFP expression 199 
in the absence of Flippase (data not shown). In contrast, concatenation of 200 
hsp70Bb and SV40 terminators, successfully precluded unintended EGFP 201 
expression. We therefore created a version of FOFO (FOFO1.0) with the two 202 
STOPs identical to the latter (Figure 2a). FOFO1.0 was tested with publicly 203 
available stocks of FLP and mFLP5 both under the control of the strong hs 204 
promoter. Encouragingly, in the presence of both hs-FLP and hs-mFLP5 and only 205 
after hs, extensive patches of EGFP were observed in all transgenics (FOFO1.0-206 
CD2miRs-GAL4miRs, FOFO1.0-prosmiRs-GAL4miRs and FOFO1.0-bratmiRs-GAL4miRs) 207 
(Figure 2b); occasional single cells labeled with EGFP could be seen in the 208 
absence of hs (average of 0.3 per brain lobe; n=240 pooling data for FOFO1.0 and 209 
FOFO2.0 carrying CD2miRs, prosmiRs or bratmiRs with no significant difference 210 
between genotypes). Furthermore, only in the presence of the oncogenic miRs 211 
were ectopic neural stem cells (NSCs) observed (Figure 2b white-boxed insets: 212 
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note NSC density within EGFP patches in brains expressing oncogenic miRs 213 
versus controls). However, ectopic NSCs were sometimes observed also outside 214 
the EGFP domain in FOFO1.0 carrying prosmiRs or bratmiRs (Figure 2b yellow-215 
boxed inset). Because this was never seen in the absence of hs it was a Flippase-216 
dependent process, likely due to inefficient termination of Pol II following 217 
excision of only one of the STOP cassettes. We concluded that our design, 218 
containing phenotype-inducing miRs ~200 bp downstream of STOP cassettes, 219 
was a sensitive reporter of Pol II readthrough (Proudfoot 2016) and that this 220 
STOP cassette was unsuitable for our purpose. 221 
We next generated a FOFO2.0 version containing two longer and potentially 222 
stronger, STOP cassettes: the Flybow one including lamin cds and a 223 
concatenation of four SV40 terminators (Jackson et al. 2001; Hadjieconomou et 224 
al. 2011). As with FOFO1.0, in the presence of both hs-FLP and hs-mFLP5 and 225 
only after hs, extensive patches of EGFP were observed in all FOFO2.0 226 
transgenics; EGFP single cell labelling frequency was analogous to that for 227 
FOFO1.0; and only in the presence of oncogenic miRs were ectopic NSCs 228 
observed (Figure 2c white-boxed insets). This was the case for hs of 20 min and 229 
1 h. When we performed a double hs of 1.5 h each 24 h apart on FOFO2.0-230 
prosmiRs-GAL4miRs we occasionally saw tumors in the presence of only hs-mFLP5 231 
(one central brain lineage in 8 out of 12 brains, which amounts to a frequency of 232 
~0.3 % as previously reported for cross-reactivity of hs-mFLP5 with FRT sites; 233 
Hadjieconomou et al. 2011). To ascertain that there was no leaky miR 234 
transcription in the absence of detectable EGFP, we counted the number of NSCs 235 
per larval central brain lobe and saw no differences between wild-type (WT) and 236 
prosmiRs and bratmiRs  central brains, in the absence of hs or the presence of a 237 
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single Flippase (or, in the few cases where hs-mFLP5 cross-reacted with FRT 238 
sites, outside the EGFP domain) (Figure 2−figure supplement 1). Crucially, with 239 
FOFO2.0 supernumerary NSCs were never observed outside the EGFP domain 240 
(Figure 2c). In summary, the FOFO2.0 design confirmed low-frequency cross-241 
reactivity between mFLP5 and FRT sites but largely blocked miR transcription in 242 
the absence of either Flippase and successfully unblocked it in the presence of 243 
both, with perfect correspondence to EGFP reporter expression. 244 
 245 
Functionality of GAL4miRs 246 
To test efficacy of GAL4miRs, we crossed hs-FLP; hs-mFLP5,FOFO2.0-prosmiRs-247 
GAL4miRs flies to those where all neural lineages are labeled in GAL4/UAS-248 
dependent manner (GAL4 expressed in the domain of the Achaete-scute family 249 
transcription factor Asense (Zhu et al. 2006; Bowman et al. 2008) in the genotype 250 
ase-GAL4,UAS-NLS::RFP). The prediction was that wherever EGFP-labelled clones 251 
would be induced (by heat-shock) the RFP signal would be wiped out due to co-252 
expression of GAL4miRs. Indeed, following heat-shock, RFP-negative patches were 253 
observed in perfect overlap with EGFP-labeled clones, as expected from efficient 254 
GAL4 knock-down (Figure 3).  255 
This experiment also illustrates successful combination of FLP/FOFO tools with 256 
GAL4/UAS as intended for independent genetic manipulations and genome-wide 257 
screens. 258 
 259 
New enhancer-FLP(D) transgenics 260 
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The next step was to employ FOFO2.0 to generate spatiotemporal controlled 261 
tumors in the larval CNS. Because of the report that mFLP5 can act on FRT 262 
sequences at low frequency but not the converse (Hadjieconomou et al. 2011), 263 
we used FLP for constitutive spatial control (lineage-specific enhancer-FLP) and 264 
mFLP5 for transiently-induced temporal control (hs-mFLP5). Few lineage-265 
specific FLP lines are currently available so we set out to generate some suited 266 
for our purpose. For type II lineages, we used the R19H09 and stg14 enhancers 267 
previously described to be expressed therein (Bayraktar et al. 2010; Wang et al. 268 
2014). We then browsed images reporting larval CNS expression of a large 269 
collection of Drosophila GAL4 lines (Manning et al. 2012) and selected twenty-six 270 
with restricted expression for further analysis. Induction of pros or brat tumors 271 
requires that these neural tumor suppressors be downregulated in progenitors, 272 
not in differentiated progeny. We thus screened selected GAL4 lines for the 273 
ability to induce supernumerary NSCs (inferred by larger reporter gene domain) 274 
when crossed to prosRNAi – a functional screen for expression in neural 275 
progenitors. Ones of interest were further tested for the ability to induce 276 
supernumerary NSCs also when crossed to bratRNAi. Downregulation of pros 277 
should induce supernumerary NSCs in all central brain lineages (type I or II) 278 
whereas downregulation of brat should induce supernumerary NSCs only in type 279 
II. Furthermore, because we aimed to generate lines to induce an irreversible 280 
intrachromosomal recombination event, it was relevant to check not only 281 
expression at a particular timepoint but the “complete” expression pattern from 282 
onset, permanently reported by a FLP-out event. Altogether, we chose 9 283 
enhancers from which to generate FLP lines (Figure 4−Figure supplement 1). 284 
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Spatiotemporal control is constrained by the dynamics of the enhancer-FLP. The 285 
degree of reproducibility of FOFO-induced tumors depends on reproducibility of 286 
the expression domain of FLP, the strength of this expression and recombination 287 
efficiency. We employed a mutated form of FLP called FLP(D), which at position 288 
5 contains an aspartic acid instead of glycine residue (Babineau et al. 1985) and 289 
is reported to be at least ten-fold more efficient than the original (Nern et al. 290 
2011). Two different promoters were compared: that of hsp70 and the 291 
Drosophila Synthetic Core Promoter (DSCP) employed in the generation of the 292 
GAL4 lines tested (Pfeiffer et al. 2008; Han et al. 2011). In all cases, expression 293 
controlled by the hsp70 promoter was less widespread relative to that controlled 294 
by the DSCP (Figure 4), which could be due either to less background or 295 
sensitivity. Aiming for spatial restriction, we used the hsp70 promoter lines for 296 
subsequent experiments. 297 
 298 
FLP cross-reactivity with mFRT71 at very low frequency 299 
Newly generated enhancer-FLP lines containing the hsp70 promoter were tested 300 
by crossing to FOFO2.0-prosmiRs-GAL4miRs. The prediction was that no induction of 301 
supernumerary NSCs or EGFP expression would occur in progeny, whether or 302 
not heat-shocked, since hs-mFLP5 was not provided. Most lines behaved as 303 
expected (no EGFP clusters containing supernumerary NSCs in the absence of hs: 304 
0/33 for R14E01; 0/41 for R73G11; 0/31 for R19H09; 0/30 for R51F05; 0/36 305 
for R71A05) but some enhancer-FLPs did very occasionally lead to induction of 306 
EGFP clusters containing supernumerary NSCs in the absence of hs (1/34 for 307 
R66B05; 5/39 for R12H06; 3/40 for R16C01; 4/28 for stg14); in all cases with a 308 
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single spurious clone per brain. This indicates that FLP can cross-react with very 309 
low frequency with non-cognate mFRT71 sites (overall frequency of ~0.04 % 310 
based on the number of such clones within the ~100 neural lineages per central 311 
brain; INPs were not included in this calculation, accounting for which would 312 
result in an even lower frequency). This cross-reactivity was never detected 313 
when crossing hs-FLP alone to FOFO2.0 lines even following long double heat-314 
shocks (Figure 2−supplement Figure 1), suggesting that this phenomenon is 315 
either due to the FLP(D) structural variation, its enhanced recombination 316 
efficiency, and/or the fact that it is provided constitutively by the spatially-317 
restricted enhancers as opposed to transiently via a hs-mediated pulse. In any 318 
case, the almost negligible cross–reactivity indicated that these enhancer-FLP 319 
lines could be used for our purpose. 320 
 321 
FOFO2.0-induced tumor reproducibility 322 
Each of the FOFO2.0 transgenics (FOFO2.0-CD2miRs-GAL4miRs, FOFO2.0-prosmiRs-323 
GAL4miRs and FOFO2.0-bratmiRs-GAL4miRs) was next recombined with hs-mFLP5. 324 
We then crossed these recombinants to enhancer-FLP(D) lines before combining 325 
them into a single stock. As expected, EGFP-labelled supernumerary NSCs were 326 
consistently observed following hs (Figure 5a). It was possible to combine all 327 
transgenes in a single animal stock with the exception of R12H06-FLP(D) and 328 
FOFO2.0-prosmiRs-GAL4miRs, which was likely because this was the only one with a 329 
reasonable degree of tumor induction in the absence of heat-shock (Figure 5b). 330 
Following heat-shock, patches of EGFP-labelled supernumerary NSCs were 331 
observed for all enhancer-FLP(D) lines, with both hs-mFLP5;FOFO2.0-CD2miRs-332 
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GAL4miRs (controls) and hs-mFLP5;FOFO2.0-prosmiRs-GAL4miRs but only the latter 333 
presented tumors (Figure 5a). Concerning reproducibility, in the first instance 334 
we were looking for symmetry between brain lobes, suggestive of near-complete 335 
extent of recombination within the enhancer domain. The heat-shock regime 336 
that led to best tumor reproducibility in this regard was a double pulse of 1.5 h 337 
each, with the first at the end of embryogenesis and a second during L1 (when 338 
brain NSCs are still quiescent), thus providing two doses of mFLP5 ~24 h apart 339 
without intervening NSC divisions (Figure 6). We used brat tumors to test a 340 
number of conditions. With hs-mFLP5;FOFO2.0-bratmiRs-GAL4miRs following heat-341 
shock, patches of EGFP-labelled supernumerary NSCs were efficiently generated 342 
with stg14-FLP(D) but rarely observed for R19H09-FLP(D) (Figure 6a), reflecting 343 
the different expression dynamics of the two enhancers. We then compared 344 
reproducibility dependence on different recombinase loading regimes: 2 versus 345 
1 hs; and 2 versus 1 copy of enhancer-FLP(D). Tumors were largest when cells 346 
were delivered double-loads of each of the recombinases (2 hs in homozygous 347 
enhancer-FLP(D) animals) and smallest when a single dose of each recombinase 348 
was provided (Figure 6b). The double-load of mFLP5 and of FLP(D) greatly 349 
reduced tumor asymmetry between lobes (Figure 6c). In summary we were able 350 
to generate spatiotemporally-controlled lineage-restricted labeled CNS tumors 351 
in a single stock in the absence of the GAL4/UAS system.  352 
 353 
Discussion 354 
We engineered genetic tools with which to generate labeled lineage-restricted 355 
CNS tumors (applicable to any other deleterious genetic perturbation) in a single 356 
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stock, and independently of GAL4/UAS. We demonstrate successful combination 357 
of novel FLP/FOFO tools with GAL4/UAS and efficacious GAL4 knock-down 358 
within domains of FLP/mFLP5 and GAL4 intersection. This validates our tool for 359 
independent genetic manipulations in strictly non-overlapping domains, which is 360 
transformative for the study of cell non-autonomous effects. Our design opens up 361 
for the first time the ability to perform efficient genome-wide screening for non-362 
autonomous effects on deleterious genotypes.  363 
We show that employment of 4 miRs is efficacious and permits simultaneous 364 
downregulation of multiple genes in the labeled domain; furthermore, T2A 365 
sequences can be added for simultaneous overexpression of coding sequences in 366 
addition to that for a reporter. The system can be used also to refine spatial 367 
domains, intersecting various enhancer-recombinases (in addition or not to hs 368 
control). 369 
The sensitivity of our design (with miR expression inducing a readily detectable 370 
and quantifiable phenotype even in non-labelled cells) allowed us to define STOP 371 
cassettes appropriate to curb even short Pol II readthrough. The discrete number 372 
of progenitors from which tumors are initiated provided a convenient platform 373 
to quantify Flippase cross-reaction and revealed low-level cross-reaction of 374 
FLP(D) with mFRT71 sites, not described before. The degree of tumor 375 
reproducibility reported differences in expression dynamics of the lineage-376 
restricted enhancers (eg., as seen by more asymmetric brat tumors with R19H09-377 
FLP(D) than with stg14-FLP(D)) and incomplete extent of recombination within 378 
the enhancer domain. Reproducibility could be improved by increased loading of 379 
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recombinases so in cases where reproducibility is desired we recommend using 380 
multiple copies of recombinase transgenes. 381 
With this setup, any desired GAL4 line can now be added to the stock containing 382 
the other elements (spatially restricted-FLP, hs-mFLP5, FOFO) and screens can 383 
be performed with a number of convenient criteria. For example, the presence of 384 
larval neural tumors induces developmental delay whose extent is proportional 385 
to tumor size (our unpublished observation); and in some lineages leads to adult 386 
sub-lethality (i.e., presence of adults bearing tumors in a sub-Mendelian 387 
proportion). Therefore, the extent of developmental delay and of adult escapers 388 
can be used as first-pass proxies for tumor size, for speedy screening of non cell-389 
autonomous modifiers of these parameters. Tumor volume can be subsequently 390 
measured directly. Additionally, a FOFO version containing a Luciferase reporter 391 
can be generated in order to use Luciferase activity as an efficient method of 392 
quantifying reporter-expressing cells (in our case tumor volume) in 393 
homogenized tissue (Homem et al. 2014). 394 
Custom-made FOFO tools can be applied to any desired topic and cell types. 395 
Control flies (those with miRs against CD2) will be available ‘off the shelf’ and 396 
experimental ones can be generated by either gene synthesis or modification of 397 
the control plasmid; or by CRISPR-modification of control host flies. It would be 398 
interesting to compare efficacy of these strategies as host flies could contain 399 
already other modules of interest. Other recombinase pairs can also be employed 400 
where mFLP5/FLP cross-reactivity is a concern. Within the CNS, other 401 
applications include investigating cell non-autonomous modifications of axon 402 
misguidance, perturbed arbor growth or synapse formation, roles of glia on 403 
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neurodegeneration, etc. Furthermore, even without gene perturbations, the 404 
FOFO tool allows sparse labeling of specifically targeted cells (sparseness 405 
achieved by short heat-shock and cell-type targeting provided by enhancer-FLP), 406 
which is extremely useful for studying cellular morphology and/or migration. 407 
Beyond the CNS, the resurgence of interest in metabolism and physiology, for 408 
example, has had strong contribution from Drosophila research (Rajan and 409 
Perrimon 2013). These are disciplines that involve interplay between cell types 410 
and different organs and tools like the ones described here will undoubtedly 411 
propel them forward. 412 
The principles of the FOFO design can be applied to other model organisms 413 
where distinct site-specific recombinases work, such as is the case for zebrafish 414 
and mouse (Nern et al. 2011; Femi et al. 2016; Carney and Mosimann 2018; 415 
Yoshimura et al. 2018) for refined spatial and/or temporal control of gene 416 
expression. In zebrafish, heat-shock induced gene expression allows for faster 417 
and/or focal induction of gene expression as compared to drug-induced 418 
expression (Halloran et al. 2000). Direct translation of a FOFO tool with the aim 419 
here described (large-scale screening for non-autonomous effects) is feasible in 420 
zebrafish by employment of the GAL4/UAS or Q/QUAS systems (Subedi et al. 421 
2014; Kawakami et al. 2016). In mouse, one way thermal shock can be focally-422 
induced (thus minimizing unwanted damage of most cells) is by Brownian 423 
motion of iron oxide nanoparticles when subject to a magnetic field. Once 424 
injected into specific tissues, these nanoparticles remain static and can be 425 
visualized by magnetic resonance imaging (Pankhurst et al. 2003), which means 426 
the site of injection, and therefore of heat-shock, can be located any time post-427 
injection. Translating the example of this study into mice, induction of 428 
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tumorigenesis focally in specific cell types by a combination of heat-shock and a 429 
cell-type specific recombinase, in a way that allows identification of exactly 430 
where the tumor was initiated, will be invaluable to study the earliest events in 431 
mammalian tumorigenesis. This is largely a “black box” in in vivo mammalian 432 
cancer studies, with assumed extrapolation from in vitro findings, since by the 433 
time a tumor can be visualized it is usually already of a substantially advanced 434 
stage. FOFO applications are thus myriad and versatile. 435 
 436 
Materials and Methods 437 
Plasmid backbone. A modified pCaSpeR plasmid containing an actin5C 438 
promoter and a PhiC31-Integrase attB site was kindly provided by C. Alexandre 439 
and further modified as described next. To enhance expression and avoid 440 
positional effects, gypsy insulators were amplified from pVALIUM2024 adding 5’ 441 
EcoRI and XhoI, and 3’ BamHI and NheI restriction sites: the gypsy PCR product 442 
digested with EcoRI and NheI was cloned into identical sites in the modified 443 
pCaSpeR, making act5C-gypsy1; the gypsy PCR product digested with XhoI and 444 
BamHI was cloned into identical sites in act5C-gypsy1, making act5C-gypsy2. To 445 
minimise recombination, this plasmid as well as its FOFO derivatives were best 446 
grown in XL10-Gold Ultracompetent Cells (Agilent Technologies, Cat. No. 447 
200314) at 30 °C at 150 rpm.  448 
FOFO modules. An initial FOFO insert containing CD2miRs-GAL4miRs and 449 
restriction sites at key locations for modularity was generated by gene synthesis 450 
(Integrated DNA Technologies) and cloned into XhoI-NotI sites in act5C-gypsy2. 451 
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Short hairpin design and exchange. All miR sequences were embedded in the 452 
Drosophila miR-1 stem-loop backbone (Haley et al. 2008), within the ftz intron 453 
(Haley et al. 2010). Control miRs were those previously used to downregulate 454 
CD2 (Yu et al. 2009); both GAL4 miRs and one each for pros and brat were 455 
sequences selected by the Transgenic RNAi Project (TRiP; Ni et al. 2011); other 456 
pros and brat miRs were selected by us (sequences below) from the output of the 457 
Designer of siRNA (DSIR) software (Vert et al. 2006; 458 
http://biodev.extra.cea.fr/DSIR/DSIR.html). In brief, target mRNA sequences 459 
were fed into the software and output sequences BLASTed against the Drosophila 460 
transcriptome; sequences with ≥ 16-bp contiguous matches to other targets 461 
were excluded. Hairpin sequences targeting pros or brat along with ones 462 
targeting GAL4, flanked by AscI on the 5’ end and AvrII on the 3’ end, were 463 
generated by gene synthesis (GenScript). The AscI-AvrII fragments were cloned 464 
into identical sites in FOFO1.0, making FOFO1.0-prosmiRs-GAL4miRs or FOFO1.0-465 
bratmiRs-GAL4miRs. The restriction sites (lowercase) and hairpin sequences (sense 466 
and antisense indicated in bold) used in this study were: 467 
GAL4miRs:  468 
cctaggAACATCCCATAAAACATCCCATATTCAGCCGCTAGCAGTCAGGATTATTTGT469 
ACAAGATATAGTTATATTCAAGCATATATCTTGTACAAATAATCCTGGCGAATTC470 
AGGCGAGACATCGGAGTTGAAACTAAAACTGAAATTTACTAGAAAACATCCCATAAA471 
ACATCCCATATTCAGCCGCTAGCAGTTCGGAAGAGAGTAGTAACAAATAGTTATAT472 
TCAAGCATATTTGTTACTACTCTCTTCCGAGCGAATTCAGGCGAGACATCGGAGTT473 
GAAACTAAAACTGAAATTTCCTAGG 474 
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prosmiRs: 475 
ggcgcgccAACATCCCATAAAACATCCCATATTCAGCCGCTAGCAGTCAGGATGTGGA476 
ACAAGAACAATAGTTATATTCAAGCATATTGTTCTTGTTCCACATCCTGGCGAATT477 
CAGGCGAGACATCGGAGTTGAAACTAAAACTGAAATTTACTAGAAAACATCCCATAA478 
AACATCCCATATTCAGCCGCTAGCAGTTAGCAGTAGTAGTAACAATAATAGTTATA479 
TTCAAGCATATTATTGTTACTACTACTGCTAGCGAATTCAGGCGAGACATCGGAGT480 
TGAAACTAAAACTGAAATTTCCTAGG 481 
bratmiRs:  482 
ggcgcgccAACATCCCATAAAACATCCCATATTCAGCCGCTAGCAGTCTGTGTCAAGGT483 
GTTCAACTATAGTTATATTCAAGCATATAGTTGAACACCTTGACACAGGCGAATTC484 
AGGCGAGACATCGGAGTTGAAACTAAAACTGAAATTTACTAGAAAACATCCCATAAA485 
ACATCCCATATTCAGCCGCTAGCAGTCGGCGTGGTGGTCAACGACAATAGTTATAT486 
TCAAGCATATTGTCGTTGACCACCACGCCGGCGAATTCAGGCGAGACATCGGAGTT487 
GAAACTAAAACTGAAATTTCCTAGG 488 
STOP cassettes. FOFO1.0 contained two identical STOP cassettes consisting of 489 
hsp70Bb (Nern et al. 2011) and SV40 terminators. FOFO2.0 contained a first 490 
STOP cassette consisting of the lamin cds plus hsp70Aa and hsp27 polyA 491 
generated by PCR using FB2.0 (Hadjieconomou et al. 2011) as template with the 492 
primers (Forward and Reverse always indicated in this order): gat cga tcc ccg ggt 493 
acc gcg gcc gcA TAG GGA ATT GGG AAT TCG C and cga att ccc aat tcc cgt tta aaC 494 
TCG AGG GTA CCA GAT CTG (uppercase indicating complementarity to 495 
template); and a second STOP cassette consisting of four tandem SV40 polyA 496 
sequences generated by PCR using the plasmid Lox-Stop-Lox TOPO (Addgene; 497 
Jackson et al. 2001) as template with the primers: gat cga tcc ccg ggt acc gcg gcc 498 
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gcG AAG TTC CTA TAC TTT CTA G and ttt ggc ttt agt cga CTC TAG TTT AGG CGT 499 
AAT CG. Products were inserted by Gibson Assembly (NEB) into FOFO-EGFPnls 500 
backbones digested with NotI and PmeI to remove the existing STOP cassettes. 501 
Primers were designed either manually or, for Gibson Assembly, with the New 502 
England Biolabs builder tool (http://nebuilder.neb.com/).  503 
Reporter. The reporter gene used was EGFP, fused in its N-terminal to a 504 
membrane targeting sequence (CD8), obtained by PCR from FB2.0 505 
(Hadjieconomou et al. 2011); or in its C-terminal to the SV40 NLS 506 
GSPPKKKRKVEDV (GGA TCC CCC CCC AAG AAG AAG CGC AAG GTG GAG GAC GTC 507 
TAG) engineered by Gibson Assembly (New England Biolabs) from a sequence 508 
kindly provided by G. Struhl and including a Kozak consensus. The 3’UTR used 509 
was His2av3’UTR-PolyA (Manning et al. 2012).  510 
Enhancer-FLPs. For the enhancer-FLP(D) constructs, the plasmid pDEST-511 
HemmarG (Addgene; Han et al. 2011) was modified using Gibson Assembly (New 512 
England Biolabs) as described next. CD4-tdGFP cds was removed with XhoI and 513 
XbaI and replaced by a PCR fragment encoding FLP(D) obtained from pJFRC150-514 
20XUAS-IVS-Flp1::PEST (Addgene; Nern et al. 2011) with the primers: cct ttt cgt 515 
tta gcc aag act cga gAA TCA AAA TGC CGC AGT TTG and act ggc tta gtt aat taa ttc 516 
tag att aAA TAC GGC GAT TGA TGT AG. We call the resulting plasmid pDEST-517 
Hemmar-FLP(D). This was transformed into One Shot® ccdB Survival™ 2 T1R 518 
Competent Cells (Life Technologies, Cat. No. A10460). A modified version of 519 
pDEST-Hemmar-FLP(D) containing the DSCP promoter (Pfeiffer et al. 2008) and 520 
the ftz intron (Haley et al. 2010) was generated using Gibson Assembly (New 521 
England Biolabs) using pBPGUw as a template. pDEST-HemmarG was digested 522 
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with BbvcI and XbaI, removing part of the ccdB cds as well as the hsp70 523 
promoter, the zeste intron and CD4-tdGFP cds. PCR fragments containing the 524 
sequences for completing the ccdB cds as well as for the DSCP promoter, ftz 525 
intron and FLP(D) cds were obtained using the primers: gga aaa tca gga agg gat 526 
ggc tga ggT CGC CCG GTT TAT TGA AAT G and cgg cca att cAG CTG AAC GAG AAA 527 
CGT AAA ATG (attR1 + ccdB cds), tcg ttc agc tGA ATT GGC CGC GTT TAA AC and 528 
gat tct cga gCC TGC AGG TCT TTG CAA TC (DSCP and ftz intron), gac ctg cag gCT 529 
CGA GAA TCA AAA TGC C and act ggc tta gtt aat taa ttc tag atc tag att aAA TAC 530 
GGC GAT TGA TGT AG (FLP(D) cds) and assembled into the BbvcI-XbaI pDEST-531 
HemmarG fragment. We call the resulting plasmid pDEST-Hemmar-DSCP-ftz-532 
FLP(D). 533 
Enhancer fragments were generated by PCR from gDNA and cloned into 534 
pENTR/D-TOPO (Life Technologies, Cat. No. K2400-20). Primer sequences 535 
contained CACC at the 5’ end of the forward primer for Gateway cloning. LR 536 
reaction products between pENTR/D-TOPO containing enhancer fragments and 537 
pDEST-Hemmar-FLP(D) or pDEST-Hemmar-DSCP-ftz-FLP(D) were used to 538 
generate transgenic flies. 539 
Drosophila stocks and transgenesis. hs-FLP, UAS-CD8::GFP, UAS-bratSH, UAS-540 
prosSH/CyO and Janelia Farm GAL4 lines were obtained from the Bloomington 541 
Stock Centre; act>STOP>GAL4,UAS-GFP was a gift from W. Chia; UAS-542 
FLP,tub>STOP>GAL4,UAS-CD8::GFP was a gift from M. Landgraf; ase-GAL4 543 
recombined with UAS-myr::RFP was a gift from A. Bailey. Bc/CyO; hs-mFLP5/TM2 544 
was a gift from I. Salecker. 545 
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PhiC31 Integrase-mediated transgenesis was performed by BestGene Inc. into 546 
attP40 (FOFO), attP18 (enhancer-FLP), attP16 (hs-FLP or hs-mFLP5) strains 547 
mutant for the gene white, which results in white eyes; since all transgenes 548 
included the white gene, insertions were selected by eye color in the F1 549 
generation. For FOFO transgenesis, animals were injected and reared at 18 °C.  550 
Heat-shocks. Larvae were heat-shocked by tube emersion into a 37 °C water-551 
bath. Duration as indicated in text and/or figures. 552 
Immunohistochemistry and imaging. For immunohistochemistry, CNSs were 553 
fixed for 15 min in 3.7% formaldehyde in PBS. Mouse anti-Miranda (mAb81 554 
1/50; gift from F. Matsuzaki) was used to label NSCs. Secondary antibodies were 555 
conjugated to either Alexa-Fluor-488 or Alexa-Fluor-555 (Molecular Probes) and 556 
used at 1/500. DNA stain was TO-PRO3 iodide (Molecular Probes). Tissues were 557 
mounted in Vectashield (Vector Laboratories) and images obtained using a Zeiss 558 
LSM510 confocal microscope. Images were acquired using the same confocal 559 
(laser power, gain and pinhole) conditions. Maximum intensity z-stack 560 
projections were generated and brightness/contrast of whole images adjusted 561 
with FIJI software.  562 
Quantifications and statistics. No randomization nor blinding was used except 563 
for data shown in Figure 2 – figure supplement 1, where NSC counts were 564 
performed blind for genotype. Here, each data point corresponds to a different 565 
individual of the designated genotype or condition. Sample size calculation is 566 
unwarranted due to the small standard deviation of the number of NSCs per 567 
central brain lobe in WT and the large effect that tumour induction has on this 568 
(many standard deviations above the mean). Data was checked for normalcy via 569 
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the Liliefors test; significance of difference between each genotype and WT was 570 
tested by Ordinary One Way ANOVA, multiple comparisons. For Figure 6, a 571 
complete Z-stack was acquired for every brain (both lobes). Quantification of 572 
tumor volume in each lobe was performed with Amira-Avizo Software (Thermo 573 
Scientific) using overlapping EGFP and anti-Miranda to identify tumors. Here, 574 
tumors were traced throughout the Z-stack to generate the volume of the traced 575 
tumour using the segmentation tool in the software package. Tumor volume of 576 
each animal was obtained by summing the volume of both brain lobes. The 577 
proportional difference of tumor volumes between brain lobes of each animal 578 
was obtained by subtracting the smaller volume (S) from the bigger volume (B) 579 
and dividing this by the sum of the two (S+B), i.e., (B-S)/(B+S). Significance of 580 
difference between each condition was tested by Kruskal-Wallis with Dunn’s 581 
multiple comparisons test as post hoc analysis. In addition, the difference 582 
between variances of each condition was tested with the Levene’s test. Each 583 
experiment was performed twice (biological replicates). Biological replicates 584 
refer to biologically distinct samples (independent crosses) grown in the same 585 
conditions and undergone the experimental procedure; sample number is 586 
indicated in each appropriate figure legend. No data was excluded. Statistical 587 
tests and graphs were generated using Prism software.  588 
Reagent availability. Plasmids and transgenic flies are deposited in stock 589 
centres. Sequence of pFOFO2.0-CD2miRs-GAL4miRs-EGFPnls is provided as 590 
Supplementary File 1. 591 
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Figure and Figure Supplement Legends 761 
Figure 1 FOFO design and application.  (a) FOFO construct design: the actin5C 762 
promoter is blocked from inducing transcript expression by two efficient 763 
transcriptional terminator (STOP) cassettes. Each of these is flanked by FRT or 764 
mFRT71, specifically recognized by FLP and mFLP5, respectively. Therefore, 765 
miRs and EGFP will only be expressed in cells containing the two flippases. 766 
Spatial and temporal control is achieved by providing a spatially restricted FLP 767 
and hs-induced mFLP5. SD, splice donor; SA, splice acceptor. Following excision 768 
of the fushi tarazu (ftz) intron, miRs are processed without detriment to reporter 769 
expression. Gypsy insulators minimize position effects whilst enhancing 770 
expression levels; attB sites allow site-specific insertion into attP-containing host 771 
strains.  (b) Schematic of FOFO application. With the insertion sites chosen for 772 
this study, flies of the following genotype can be generated: enhancer-FLP; hs-773 
mFLP5, FOFO-EGFP; enhancer2-GAL4 (exemplifying with the GAL4 transgene on 774 
the third chromosome, though it could be placed elsewhere). Expression of 775 
deleterious sequences (either knock-down by miRs or overexpression alongside 776 
the reporter by means of T2A) can be induced (by heat-shock) in a single fly 777 
stock (without need to cross) carrying FOFO, a lineage-specific enhancer1-FLP 778 
and hs-mFLP5. The point is then to add in the same flies (F0 generation) a GAL4 779 
transgene (enhancer2-GAL4) and cross to UAS responders. The FOFO containing 780 
stock expresses FLP in the spatially restricted domain defined by enhancer1 781 
(yellow) in a tissue represented by the grey shape. FLP expression will 782 
constitutively excise the first STOP cassette but the presence of a second STOP 783 
cassette precludes expression of anything downstream unless flies are subject to 784 
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hs. The F1 progeny expresses a transgene (purple) in the GAL4-expressing 785 
domain defined by enhancer2 (black). Following hs, mFLP5 expression leads to 786 
excision of the second STOP cassette and thus expression of miRs and EGFP in 787 
the domain covered by the lineage-specific enhancer. Even if the domain of the 788 
latter overlaps with that of enhancer2 as depicted, GAL4 miRs will delete GAL4 789 
expression in the EGFP-expressing domain so that the GAL4 domain never 790 
overlaps with that of enhancer1 and only cell nonautonomous effects are 791 
assessed. (c) Schematic representation of a FOFO application with the tools 792 
designed for this study. EGFP-labelled neural tumors (green) are generated 793 
within brain lobes (grey shape) in a stock also carrying a GAL4 expressed in glia 794 
(purple). Crossing this stock to any UAS-responder lines (could be genome-wide 795 
gain- or loss-of-function) will allow identification of genes whose glial expression 796 
affects tumor size. 797 
 798 
Figure 1−Figure supplement 1. (a) Schematics of Drosophila type I and II larval 799 
brain lineages with color-coded cell types; key on the right. NSC, neural stem 800 
cells (type I in red and type II in purple); GMC, ganglion mother cell; INP, 801 
intermediate neural progenitor. Wild-type (WT), pros-/- and brat-/- lineages 802 
(tumorigenic) are schematized. In pros mutant lineages, GMCs revert to NSCs in 803 
type I, and to INPs in type II; brat mutation affects only type II lineages, in which 804 
INPs revert to NSCs.  (b) Schematic of the Drosophila CNS and its regionalization: 805 
each brain lobe consists of central brain and optic lobe regions; each central 806 
brain contains ~100 NSCs: 8 type II (purple circles) and ~90 type I (red circles). 807 
Posterior to the brain is the ventral nerve cord (VNC). (Optic lobe and VNC NSCs 808 
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are represented by grey circles within amplified schematic). The region outlined 809 
by dashed line is the neuropil. 810 
 811 
Figure 2 FOFO1.0 versus FOFO2.0.  (a) FOFO.1.0 and FOFO2.0 differ in their 812 
STOP cassettes (drawn roughly to scale unlike remainder of construct); shapes 813 
are colour-coded as in Figure 1a. (b) Wandering third-instar larval brain lobes. 814 
In the absence of hs, the brains of animals carrying FOFO1.0 as well as hs-FLP1 815 
and hs-mFLP5 look WT. Following hs, miR and EGFP expression is induced and 816 
supernumerary NSCs characteristic of these tumors are generated within the 817 
EGFP domain (notice NSC density in white-boxed insets). However, 818 
supernumerary NSCs outside the EGFP domain were also observed (notice NSC 819 
density in yellow-boxed inset, comparable to that of white-boxed inset of same 820 
sample). (c) Wandering third-instar larval brain lobes. In the absence of hs, the 821 
brains of animals carrying FOFO2.0 as well as hs-FLP1 and hs-mFLP5 look WT. 822 
Following hs, miR and EGFP expression is induced and supernumerary NSCs 823 
characteristic of these tumors are generated only within the EGFP domain 824 
(white-boxed insets). All images are maximum intensity projections of Z-series 825 
but those of brains containing tumors are projections of only a few optical 826 
sections. Images are of a representative example obtained from two biological 827 
replicates (n>10 per condition). Scale bar: 100 μm. 828 
 829 
Figure 2−Figure supplement 1. FOFO2.0 precludes formation of 830 
supernumerary NSCs unless both FLP and mFLP5 are provided. 831 
Quantification of the number of NSCs (identified by expression of Miranda) per 832 
brain lobe in third-instar larvae of the indicated genotypes (above histograms) 833 
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crossed to either both hs-FLP and hs-mFLP5 or just one of them (as indicated 834 
below graph), subjected or not to heat-shock (indicated by thermometers). One 835 
brain lobe per animal was picked at random. Histograms heights represent the 836 
mean and error bars the S.D.. There was no statistically significant difference 837 
between any of the conditions. Data points shown were collected from two 838 
biological replicates (in order of histograms presented: n=13; n=12, p=0.7177; 839 
n=12, p=0.964; n=11, p=0.9999; n=11, p=0.9899; n=11, p=0.9995; n=12, 840 
p=0.9963). 841 
* At low frequency (0.3 %) tumors were observed in heat-shocked animals 842 
carrying only hs-mFLP5 and FOFO2.0-prosshmiRs-GAL4shmiRs; tumors were labeled  843 
by EGFP expression and in those cases only NSCs outside the green domain were 844 
counted. 845 
 846 
 Figure 2−Figure supplement 1−source data 1. 847 
 848 
Figure 3 GAL4 miRs efficiently downregulate GAL4. hs-FLP; hs-mFLP5,FOFO2.0-849 
prosmiRs-GAL4miRs flies were crossed with ase-GAL4,UAS-NLS::RFP (which express 850 
RFP in all CNS lineages) flies. Wandering third-instar larval brain lobes of 851 
progeny are shown. Following heat-shock, EGFP and GAL4miRs are expressed by 852 
the FOFO construct leading to RFP-negative patches in perfect overlap with 853 
EGFP-labeled clones as expected from efficient GAL4 knock-down. Images are of 854 
a representative example obtained from two biological replicates (n>10 per 855 
condition). Scale bar: 100 m.  856 
 857 
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Figure 4 The hsp70 promoter induces less expression of enhancer-FLP(D) 858 
lines than the DSCP promoter. New enhancer-FLP(D) lines were crossed to 859 
act>STOP>GAL4,UAS-GFP and wandering third-instar larval CNSs imaged for 860 
endogenous GFP expression. All genotypes were processed in parallel and 861 
imaged with identical conditions. In all cases, expression controlled by the hsp70 862 
promoter was less relative to that controlled by the DSCP, which could be due 863 
either to less background or sensitivity. Images are of a representative example 864 
obtained from two biological replicates (n>10 per condition). Scale bar: 100 m. 865 
 866 
Figure 4−Figure supplement 1. Examples of wandering third-instar larval CNSs 867 
of indicated genotypes. The left column contains images of ventral nerve cords 868 
and all other images are of brain lobes. All images are maximum intensity 869 
projections of Z-series. Images are of a representative example obtained from 870 
two biological replicates (n>10 per condition). Scale bar: 100 μm. 871 
 872 
Figure 5 FOFO2.0-mediated lineage-restricted CNS tumor generation 873 
within a single stock. (a) Wandering third-instar CNSs of hs-induced labeled 874 
tumors obtained with eight enhancer-FLP(D) and hs-mFLP5,FOFO2.0-prosmiRs-875 
GAL4miRs compared with non-tumor labeled lineages (same enhancer-FLP(D)s 876 
with hs-mFLP5,FOFO2.0-CD2miRs-GAL4miRs) and background (no hs) tumor 877 
incidence. In the absence of heat-shock, tumors were occasionally induced with 878 
incomplete penetrance (inset in top right; numbers indicate frequency of CNSs 879 
devoid of tumours) but these were much smaller than those intentionally 880 
induced by heat-shock. (b) Wandering third-instar larval CNSs from progeny of 881 
the cross between indicated genotypes. When subject to heat-shock extensive 882 
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tumors are induced throughout the CNS (labeled in green and containing 883 
supernumerary NSCs). In the absence of heat-shock tumors (albeit much 884 
smaller) are induced. (a-b) All images are maximum intensity projections of Z-885 
series; obtained from two biological replicates (n>10 per condition and exact 886 
number indicated for the background condition in a – third column). Scale bar: 887 
100 m. 888 
 889 
Figure 6 Selection of appropriate enhancer-FLP(D) in combination with hs-890 
mFLP5 allows reproducible CNS tumor generation within a single stock via 891 
FOFO2.0. (a) Representative images of white prepupal CNSs in which the stated 892 
enhancer-FLP was employed as either homozygous or heterozygous as indicated, 893 
with prosmiRs or bratmiRs with the hs regimes indicated (arrow points at rare 894 
tumor generated with R19H09-FLP). All images are maximum intensity 895 
projections of Z-series. Scale bar: 100 m. (b) Quantification of EGFP volumes of 896 
bratmiRs tumors. (c) Normalized tumor volume differences between brain lobes. 897 
* p < 0.05; ** p < 0.01; *** p < 0.001; n.s. = not significant. 898 
 899 
Figure 6− source data 1. 900 
 901 
Supplementary File 1. Sequence of pFOFO2.0-CD2miRs-GAL4miRs-EGFPnls. 902 
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Figure	 1	 FOFO	 design	 and	 application.	 (a)	 FOFO	 construct	 design:	 the	 actin5C	 promoter	 is	 blocked	 from	 inducing	transcript	expression	by	two	ef>icient	transcriptional	terminator	(STOP)	cassettes.	Each	of	these	is	>lanked	by	FRT	or	mFRT71,	speci>ically	recognized	by	FLP	and	mFLP5,	respectively.	Therefore,	miRs	and	EGFP	will	only	be	expressed	in	cells	containing	the	two	>lippases.	Spatial	and	temporal	control	is	achieved	by	providing	a	spatially	restricted	FLP	and	hs-induced	mFLP5.	SD,	splice	donor;	SA,	splice	acceptor.	Following	excision	of	 the	 fushi	 tarazu	 (ftz)	 intron,	miRs	are	processed	 without	 detriment	 to	 reporter	 expression.	 Gypsy	 insulators	 minimize	 position	 effects	 whilst	 enhancing	expression	 levels;	 attB	 sites	 allow	 site-speci>ic	 insertion	 into	 attP-containing	 host	 strains.	 (b)	 Schematic	 of	 FOFO	application.	With	the	insertion	sites	chosen	for	this	study,	>lies	of	the	following	genotype	can	be	generated:	enhancer-
FLP;	hs-mFLP5,	FOFO-EGFP;	enhancer2-GAL4	(exemplifying	with	the	GAL4	transgene	on	the	third	chromosome,	though	it	 could	 be	 placed	 elsewhere).	 Expression	 of	 deleterious	 sequences	 (either	 knock-down	 by	miRs	 or	 overexpression	alongside	the	reporter	by	means	of	T2A)	can	be	induced	(by	heat-shock)	in	a	single	>ly	stock	(without	need	to	cross)	carrying	 FOFO,	 a	 lineage-speci>ic	 enhancer1-FLP	 and	 hs-mFLP5.	 The	 point	 is	 then	 to	 add	 in	 the	 same	 >lies	 (F0	generation)	a	GAL4	transgene	(enhancer2-GAL4)	and	cross	to	UAS	responders.	The	FOFO	containing	stock	expresses	FLP	 in	 the	spatially	restricted	domain	de>ined	by	enhancer1	(yellow)	 in	a	 tissue	represented	by	 the	grey	shape.	FLP	expression	 will	 constitutively	 excise	 the	 >irst	 STOP	 cassette	 but	 the	 presence	 of	 a	 second	 STOP	 cassette	 precludes	expression	of	anything	downstream	unless	>lies	are	subject	to	hs.	The	F1	progeny	expresses	a	transgene	(purple)	in	the	GAL4-expressing	domain	de>ined	by	enhancer2	(black).	Following	hs,	mFLP5	expression	leads	to	excision	of	the	second	STOP	cassette	and	thus	expression	of	miRs	and	EGFP	in	the	domain	covered	by	the	lineage-speci>ic	enhancer.	Even	if	the	domain	of	 the	 latter	overlaps	with	 that	of	enhancer2	as	depicted,	GAL4	miRs	will	delete	GAL4	expression	 in	 the	EGFP-expressing	 domain	 so	 that	 the	 GAL4	 domain	 never	 overlaps	 with	 that	 of	 enhancer1	 and	 only	 cell	 non-autonomous	effects	are	assessed.	(c)	Schematic	representation	of	a	FOFO	application	with	the	tools	designed	for	this	study.	EGFP-labelled	neural	 tumors	 (green)	are	generated	within	brain	 lobes	 (grey	shape)	 in	a	stock	also	carrying	a	GAL4	expressed	in	glia	(purple).	Crossing	this	stock	to	any	UAS-responder	lines	(could	be	genome-wide	gain-	or	loss-of	function)	will	allow	identi>ication	of	genes	whose	glial	expression	affects	tumor	size.		
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Figure	 1−Figure	 supplement	 1.	 (a)	 Schematics	 of	Drosophila	 type	 I	 and	 II	 larval	 brain	lineages	with	color-coded	cell	types;	 	key	on	the	right.	NSC,	neural	stem	cells	(type	I	in	red	and	 type	 II	 in	 purple);	 GMC,	 ganglion	 mother	 cell;	 INP,	 intermediate	 neural	 progenitor.	Wild-type	(WT),	pros-/-	and	brat-/-	 lineages	(tumorigenic)	are	schematized.	 In	pros	mutant	lineages,	GMCs	revert	 to	NSCs	 in	 type	 I,	and	 to	 INPs	 in	 type	 II;	brat	mutation	affects	only	type	II	lineages,	in	which	INPs	revert	to	NSCs.	(b)	Schematic	of	the	Drosophila	CNS	and	its	regionalization:	 each	 brain	 lobe	 consists	 of	 central	 brain	 and	 optic	 lobe	 regions;	 each	central	brain	 contains	~100	NSCs:	8	 type	 II	 (purple	 circles)	 and	~90	 type	 I	 (red	 circles).	Posterior	 to	 the	 brain	 is	 the	 	 ventral	 nerve	 cord	 (VNC).	 (Optic	 lobe	 and	 VNC	 NSCs	 are	represented	by	grey	circles	within	ampliPied	schematic).	The	region	outlined	by	dashed	line	is	the	neuropil.	
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Figure	2	FOFO1.0	versus	FOFO2.0.	(a)	FOFO.1.0	and	FOFO2.0	differ	in	their	STOP	cassettes	(drawn	roughly	to	scale	unlike	remainder	of	construct);	shapes	are	colour-coded	as	 in	 Figure	 1a.	 (b)	Wandering	 third-instar	 larval	 brain	 lobes.	 In	 the	 absence	 of	 hs,	 the	 brains	 of	 animals	 carrying	 FOFO1.0	 as	well	 as	 hs-FLP1	 and	 hs-mFLP5	 look	WT.	Following	hs,	miR	and	EGFP	expression	 is	 induced	and	supernumerary	NSCs	characteristic	of	 these	 tumors	are	generated	within	 the	EGFP	domain	(notice	NSC	density	 in	white-boxed	 insets).	However,	supernumerary	NSCs	outside	the	EGFP	domain	were	also	observed	(notice	NSC	density	 in	yellow-boxed	 inset,	comparable	to	that	of	white-boxed	inset	of	same	sample).	(c)	Wandering	third-instar	larval	brain	lobes.	In	the	absence	of	hs,	the	brains	of	animals	carrying	FOFO2.0	as	well	as	hs-FLP1	and	hs-mFLP5	look	WT.	Following	hs,	miR	and	EGFP	expression	 is	 induced	and	supernumerary	NSCs	characteristic	of	 these	tumors	are	generated	only	within	the	EGFP	domain	(white-boxed	insets).	 All	 images	 are	 maximum	 intensity	 projections	 of	 Z-series	 but	 those	 of	 brains	 containing	 tumors	 are	 projections	 of	 only	 a	 few	 optical	 sections.	 Images	 are	 of	 a	representative	example	obtained	from	two	biological	replicates	(n>10	per	condition).	Scale	bar:	100	µm.		
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Figure	   2−Figure	   supplement	   1	   FOFO2.0	   precludes	   formation	   of	   supernumerary	   NSCs	  unless	  both	  FLP	  and	  mFLP5	  are	  provided.	  QuantiAication	  of	  the	  number	  of	  NSCs	  (identiAied	  by	  expression	  of	  Miranda)	  per	  brain	   lobe	   in	   third-­‐instar	   larvae	  of	   the	   indicated	  genotypes	  (above	  histograms)	  crossed	  to	  either	  both	  hs-­‐FLP	  and	   	  hs-­‐mFLP5	  or	   just	  one	  of	   them	   	  (as	  indicated	  below	  graph),	   subjected	   or	   not	   to	   heat-­‐shock	   (indicated	  by	   thermometers).	  One	  brain	   lobe	  per	  animal	  was	  picked	  at	   random.	  Histograms	  heights	   represent	   the	  mean	  and	  error	   bars	   the	   S.D..	   There	   was	   no	   statistically	   signiAicant	   difference	   between	   any	   of	   the	  conditions.	   Data	   points	   shown	  were	   collected	   from	   two	   biological	   replicates	   (in	   order	   of	  histograms	   presented:	   n=13;	   n=12,	   p=0.7177;	   n=12,	   p=0.964;	   n=11,	   p=0.9999;	   n=11,	  p=0.9899;	  n=11,	  p=0.9995;	  n=12,	  p=0.9963).	  	  *	  At	  low	  frequency	  (0.3	  %)	  tumors	  were	  observed	  in	  heat-­‐shocked	  animals	  carrying	  only	  hs-­‐mFLP5	  	  and	  	  FOFO2.0-­‐prosshmiRs-­‐GAL4shmiRs;	  	  tumors	  	  were	  	  labeled	  	  by	  EGFP	  expression	  and	  in	  those	  cases	  only	  NSCs	  outside	  the	  green	  domain	  were	  counted.	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Figure	3	 GAL4	miRs	 ef,iciently	 downregulate	GAL4.	hs-FLP;	hs-mFLP5,FOFO2.0-prosmiRs-
GAL4miRs	 ,lies	were	 crossed	with	 ase-GAL4,UAS-NLS::RFP	 (which	 express	 RFP	 in	 all	 CNS	lineages)	,lies.	Wandering	third-instar	larval	brain	lobes	of	progeny	are	shown.	Following	heat-shock,	 EGFP	 and	 GAL4miRs	 are	 expressed	 by	 the	 FOFO	 construct	 leading	 to	 RFP-negative	patches	 in	perfect	overlap	with	EGFP-labeled	clones	as	expected	 from	ef,icient	GAL4	knock-down.	Images	are	of	a	representative	example	obtained	from	two	biological	replicates	(n>10	per	condition).	Scale	bar:	100	µm.		
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Figure	 4	 The	 hsp70	 promoter	 induces	 less	 expression	 of	 enhancer-FLP(D)	 lines	 than	 the	 DSCP	 promoter.	 New	 enhancer-FLP(D)	 lines	 were	 crossed	 to		
act>STOP>GAL4,UAS-GFP	and	wandering	third-instar	larval	CNSs	imaged	for	endogenous	GFP	expression.	All	genotypes	were	processed	in	parallel	and	imaged	with	identical	conditions.	In	all	cases,	expression	controlled	by	the	hsp70	promoter	was	less	relative	to	that	controlled	by	the	DSCP,	which	could	be	due	either	to	less	background	or	sensitivity.	Images	are	of	a	representative	example	obtained	from	two	biological	replicates	(n>10	per	condition).	Scale	bar:	100	µm.	
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Figure	 4−Figure	 supplement	 1.	 Examples	 of	 wandering	 third-instar	 larval	 CNSs	 of	 indicated	genotypes.	The	left	column	contains	images	of	ventral	nerve	cords	and	all	other	images	are	of	brain	lobes.	 All	 images	 are	 maximum	 intensity	 projections	 of	 Z-series.	 Images	 are	 of	 a	 representative	example	obtained	from	two	biological	replicates	(n>10	per	condition).	Scale	bar:	100	µm.	
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Figure	5	FOFO2.0-mediated	lineage-restricted	CNS	tumor	generation	within	a	single	stock.	(a)	Wandering	third-instar	CNSs	 of	 hs-induced	 labeled	 tumors	 obtained	 with	 eight	 enhancer-FLP(D)	 and	 hs-mFLP5,FOFO2.0-prosmiRs-GAL4miRs	compared	 with	 non-tumor	 labeled	 lineages	 (same	 enhancer-FLP(D)s	with	 hs-mFLP5,FOFO2.0-CD2miRs-GAL4miRs)	 and	background	(no	hs)	tumor	incidence.	In	the	absence	of	heat-shock,	tumors	were	occasionally	induced	with	incomplete	penetrance	(inset	in	top	right;	numbers	indicate	frequency	of	CNSs	devoid	of	tumours)	but	these	were	much	smaller	than	 those	 intentionally	 induced	 by	 heat-shock.	 (b)	Wandering	 third-instar	 larval	 CNSs	 from	 progeny	 of	 the	 cross	between	indicated	genotypes.	When	subject	to	heat-shock	extensive	tumors	are	induced	throughout	the	CNS	(labeled	in	green	and	containing	supernumerary	NSCs).	In	the	absence	of	heat-shock	tumors	(albeit	much	smaller)	are	induced.	
(a-b)	All	 images	 are	maximum	 intensity	 projections	 of	 Z-series;	 obtained	 from	 two	 biological	 replicates	 (n>10	 per	condition	and	exact	number	indicated	for	the	background	condition	in	a	–	third	column).	Scale	bar:	100	µm.	
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Figure	  6	  Selection	  of	  appropriate	  enhancer-­‐FLP(D)	  in	  combination	  with	  hs-­‐mFLP5	  allows	  reproducible	  CNS	  tumor	  generation	  within	  a	  single	  stock	  via	  FOFO2.0.	  (a)	  Representative	  images	  of	  white	  prepupal	  CNSs	  in	  which	  the	  stated	  enhancer-­‐FLP	  was	  employed	  as	  either	  homozygous	  or	  heterozygous	  as	  indicated,	  with	  prosmiRs	  or	  bratmiRs	  with	  the	  hs	  regimes	  indicated	  (arrow	  points	  at	  rare	  tumor	  generated	  with	  R19H09-­‐FLP).	  All	  images	  are	  maximum	  intensity	  projections	  of	  Z-­‐series.	  Scale	  bar:	  100	  µm.	  (b)	  QuantiQication	  of	  EGFP	  volumes	  of	  bratmiRs	   tumors.	  (c)	  Normalized	  tumor	  volume	  differences	  between	  brain	  lobes.	  *	  p	  <	  0.05;	  **	  p	  <	  0.01;	  ***	  p	  <	  0.001;	  n.s.	  =	  not	  signiQicant.	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